In another CRISPR first, Penn researchers dose US cancer patients with gene-edited T cell therapy
CRISPR has been tested in US patients for the first time — but perhaps not in the manner you imagined.
The University of Pennsylvania has led the way dosing two patients with relapsed cancers — one with multiple myeloma and one with sarcoma — with a T cell therapy in which the T cell receptor and PD-1 protein are edited out.
Funding for the trial came partly from Tmunity, a biotech co-founded by Penn’s CAR-T visionary Carl June and helmed by Novartis vet Usman “Oz” Azam. Parker Institute for Cancer Immunotherapy, an early investor in Tmunity, is also bankrolling the trial. A Penn spokesperson confirmed the news, which was first reported by NPR.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
